|Chemical and physical data|
|Molar mass||320.82 g/mol|
|3D model (Jmol)||Interactive image|
Lesopitron (E-4424) is a selective full agonist of the 5-HT1A receptor which is structurally related to the azapirones. In 2001 it was under development by Esteve as an anxiolytic for the treatment of generalized anxiety disorder (GAD). It made it to phase II clinical trials but was apparently discontinued as no new information on lesopitron has surfaced since.
- Haj-Dahmane S, Jolas T, Laporte AM, et al. (April 1994). "Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat". European Journal of Pharmacology. 255 (1-3): 185–96. doi:10.1016/0014-2999(94)90097-3. PMID 8026543.
- Micheli F (February 2001). "Lesopitron (Esteve)". IDrugs : the Investigational Drugs Journal. 4 (2): 218–24. PMID 16032484.
- Fresquet A, Sust M, Lloret A, et al. (February 2000). "Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder". The Annals of Pharmacotherapy. 34 (2): 147–53. doi:10.1345/aph.19041. PMID 10676820.